Pfizer has made the decision to withdraw Oxbryta (voxelotor), a treatment for sickle cell disease, from all markets where it is approved. Additionally, all clinical trials evaluating voxelotor, as ...

Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...